Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin

Journal of Clinical Pharmacology

Volumn 48, Issue 12, 2008, Pages 1438-1450

  Modi, N B ^a   Kell, S ^a   Aquilina, J ^b   Rivas, D ^b  

^a ALZA CORPORATION   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dapoxetine; Orthostasis; Pharmacokinetics; Tamsulosin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DAPOXETINE; DAPOXETINE N OXIDE; DIMETHYLANILINE MONOOXYGENASE; DRUG METABOLITE; NORDAPOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TAMSULOSIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEART RATE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PREMATURE EJACULATION; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AREA UNDER CURVE; BENZYLAMINES; CROSS-OVER STUDIES; DIZZINESS; DOUBLE-BLIND METHOD; HALF-LIFE; HEADACHE; HEMODYNAMICS; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; NAPHTHALENES; RECEPTORS, ADRENERGIC, ALPHA-1; SEROTONIN UPTAKE INHIBITORS; SULFONAMIDES; SYNCOPE, VASOVAGAL;

EID: 57449111269     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008324695     Document Type: Article

References (21)

1. Laumann EO, Paik A., Rosen RC Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999 ; 281: 537-544.
2. Laumann EO, Nicolosi A., Glasser DB, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005 ; 17: 39-57.
3. Porst H., Montorsi F., Rosen RC, Gaynor L., Grupe S., Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007 ; 51: 816-824.
4. Waldinger MD, Berendsen HH, Blok BF, Olivier B., Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998 ; 92: 111-118.
5. Montague DK, Jarow J., Broderick G., et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol. 2004 ; 172: 290-294.
6. Pryor JL, Althof SE, Steidle C., et al. Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation: integrated analysis of two randomized, double-blind, placebo-controlled trials. Lancet. 2006 ; 368: 929-937.
7. Kaufman J., Rosen RC, Rowland DL, Mudumbi R., Tesfaye F., Rothman M. Improved distress related to ejaculation in men with premature ejaculation (PE) who responded to dapoxetine. Poster presented at: Annual Meeting of the American Urological Association ; May 19-24, 2007 ; Anaheim, California.
8. Buvat J., Giuliano F., Tesfaye F., Rothman M., Rivas D. Efficacy and safety of dapoxetine for premature ejaculation (PE): results from a placebo-controlled, double-blind, randomized, parallel-group study in 22 countries. Oral presentation at: 27th Annual Meeting of the Societe Internationale d'Urologie ; September 2-6, 2007 ; Paris, France.
9. McMahon C., Park NC, Zhao Y., Rothman M., Rivas D. Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Oral presentation at: 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine ; October 6-10, 2007 ; Jeju, Korea. Abstract OS05_06.
10. Modi NB, Dresser MJ, Simon M., Lin D., Desai D., Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. 2006 ; 46: 301-309.
11. Dresser MJ, Kang D., Staehr P., et al. Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal. J Clin Pharmacol. 2006 ; 46: 1023-1029.
12. de Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol. 1998 ; 34 (suppl 2). 18-28.
13. Michel MC, Grubbel B., Taguchi K., Verfurth F., Otto T., Kropfl D. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 ; 16: 21-28.
14. Roehrborn CG, Schwinn DA Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 ; 171: 1029-1035.
15. Dunn CJ, Matheson A., Faulds DM Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002 ; 19: 135-161.
16. Wilt TJ, Mac DR, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003 ;(1). CD002081.
17. Modi NB, Nath R., Wang B., Rivas D., Gupta S. Dapoxetine has no effects on hemodynamics or electrocardiographic assessments. Presented at: 10th Congress of the European Society for Sexual Medicine ; November 25-28, 2007 ; Lisbon, Portugal.
18. Djavan B., Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999 ; 36: 1-13.
19. Wolzt M., Fabrizii V., Dorner GT, et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol. 1998 ; 54: 367-373.
20. Kamimura H., Oishi S., Matsushima H., et al. Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 ; 28: 909-922.
21. National High Blood Pressure Education Program: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health-National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program ; 2004. NIH Pub. No. 04-5230.